TMO

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✓

Return

+0.93%

Status

scored

TMO is maintained at HOLD with 50% sizing given excessive entry risk at $651.98 versus a base-case fair value of ~$590. The aggressive analyst's $27.58 forward EPS projection requires 47% sequential acceleration with no historical precedent, while deteriorating technicals (7+ negative MACD sessions, 27% ATR expansion) create vulnerability into the October 28 Q3 binary catalyst. Preferred entries are the 50 SMA at ~$623 or prior breakout zone $595-$605, with hard stop at $605.

Outcome

✓

Return

-1.52%

Status

scored

Maintain TMO at current weight with a hard $622 stop (50 SMA), avoid fresh capital deployment at $660-665, and either sell November $700 calls or implement a collar (buy $600 put/sell $720 call) to harvest elevated implied volatility into the Q3 2026 binary catalyst. The structural bull case remains intact but the 5.7% reversal at $694 ATH, 7 sessions of negative MACD, and $5.8B cash drawdown for the $8.87B acquisition create a distribution signal that warrants patience until Q3 2026 earnings resolves direction.

Outcome

✓

Return

+0.83%

Status

scored

Analyst upgrades TMO to Overweight with a 4-tranche entry plan targeting 1.5-2.0% portfolio weight rather than full commitment, blending entry at ~$636 within the $621-652 zone to improve risk/reward versus chasing higher prices. Price target is $700+ on a closing basis with hard stop at $601 (below lower Bollinger Band), and Q3 2026 earnings (late October) is the binary resolution catalyst.

Outcome

✗

Return

-2.98%

Status

scored

Maintain TMO at full target weight ahead of the Q3 2026 binary catalyst (late October). Do not add at 52-week highs ($676.76) given the fresh MACD histogram flip at RSI 64.7 signaling failed follow-through, and do not trim into strength targeting $690-700. The structural stop is the 50 SMA weekly close at $619, which defines the risk boundary.

Outcome

✗

Return

+3.35%

Status

scored

Maintain TMO at current size (Hold) with the 50 SMA at $617 as the binding technical stop, not the trader's $646. Neither adding on the 10 EMA breakdown nor trimming into a defensive compounder with re-accelerating fundamentals is warranted; Q3 earnings in late October is the binary catalyst determining whether Q2's 10.5% revenue growth represents a regime change or a one-quarter anomaly.

Outcome

✓

Return

+0.35%

Status

scored

Maintain TMO at 80% of target core weight heading into Q3 2026 earnings in late October. The aggressive BUY case fails due to ~1:1 asymmetry at current $652 price with untested 50 SMA and binary Q3 catalyst 4-6 weeks out, while the conservative wait-for-$615 approach is too rigid given RSI reset from 73 to 55 and 5% consolidation from highs. The structural thesis ($6.3B FCF, 0.85 beta, 90% recurring consumables, golden cross intact at $590/$535) remains load-bearing and warrants holding, but fresh capital should wait for either a bullish close above 10 EMA ($663) with MACD histogram flip OR successful 50 SMA ($615) retest with constructive price action.

Outcome

✓

Return

-3.34%

Status

scored

Trim 10–15% of TMO exposure into the $670–685 range to lock in gains from the +55% rally off the May bottom while reducing concentration ahead of a binary Q3 2026 catalyst; maintain 85–90% of the position as the structural thesis remains intact but RSI overbought nine sessions, volume declining into highs, and four failed breakouts at $682.98 warrant tactical caution. Stand aside with new capital above $660 and hold dry powder for re-entry at $610–640 on confirmed pullback with RSI reset to 55–60 on declining volume.

Outcome

✓

Return

-0.67%

Status

scored

Maintain TMO at neutral weight without adding at current $679.61; RSI 73.83 at the year's peak with declining volume (4.6M → 1.7M) signals a weakening tape, limiting upside to +2.7% while downside extends to −4.2% to the 10 EMA, −10.3% to the 50 SMA, or −4.2% to VWMA. Hard stop on any residual position at the 10 EMA ($663.53), with fresh capital deployment deferred until either a pullback to the $651–$663 zone with RSI reset toward 55–60 on declining volume, or a confirmed daily close above $682.98 on volume ≥3M shares — both offering materially better risk/reward than chasing a stretched entry four weeks before a binary Q3 earnings catalyst.

Outcome

–

Return

+0.15%

Status

scored

Trim 15-20% of TMO into the $675-682 resistance zone to lock in gains from the +36% six-month rally, while maintaining a hard stop on the residual position at $650 daily close. Stand aside with new capital; re-engage on pullback to $620-635 with bullish reversal candle or confirmed close above $700 on above-average volume. Q3 2026 earnings in late October is the binary catalyst.

Outcome

✗

Return

+0.53%

Status

scored

Underweight rating justified by concrete earnings-quality deterioration including FCF fell 13.4% in FY2025 ($7.27B to $6.29B) on a -$1.77B working capital headwind while net income rose, while the 36.3x trailing P/E sits 50% above the 10-year median. The asymmetry presents 3-5x more downside than upside with 6.7% upside to bull target versus -31% downside on full trailing-multiple reset, supporting a decisive 35-45% trim over baseline approaches. The conservative analyst's warning about 50%+ trims replicating prior alpha-destruction errors is noted but outweighed by fundamental deterioration signals.

Outcome

✓

Return

-0.50%

Status

scored

Trim 30-35% of TMO holdings in the $670-685 zone to lock in gains from the 55%+ rally off May lows, retaining 65-70% of the position. Deploy trimmed capital 50/50 into short-duration Treasuries yielding 4.5%+ and cash for tactical redeployment, with hard stop at $598 close (50 SMA structural break) and re-entry zones at $620-635 or $595-605 on confirmed pullback with declining volume.

Outcome

✗

Return

+1.97%

Status

scored

Maintain HOLD with a calibrated 35-45% trim on price pushes above $665-668, as the structural thesis (golden cross intact, $6B+ TTM FCF, 0.85 defensive beta, Mayo JV) remains valid but elevated fundamental and technical signals (RSI 71.57, Bollinger band pierce at $671.47, FCF compression to $5.79B, net debt at $38.5B/3.28x leverage) warrant a heavier-than-normal trim execution under HOLD rather than a full underweight. Stop-loss sits at $612-615; re-entry on close above $668 with volume confirmation or on weakness at $585-605, with Q3 2026 earnings in late October serving as the binary catalyst.

Outcome

✗

Return

+1.03%

Status

scored

Analysts recommend trimming the TMO position by 25-35% to harvest gains at 52-week highs, with a hard stop at $585 and staged re-entry zones at $625-$641 and $540-$560. The shift from Hold to Underweight reflects five extension signals co-occurring at $658 alongside price above consensus target, with Q3 2026 earnings (late October) serving as the thesis-resolving catalyst. Freed capital (50-60%) should rotate into DHR and A while maintaining dry powder for TMO re-entry.

Outcome

✓

Return

-0.04%

Status

scored

Maintain TMO at HOLD with 50-70% of benchmark weight; the structural thesis (7% organic growth target, $6.24B TTM FCF, golden cross intact, $1B+ buyback) remains valid, but the current $658.76 entry offers unfavorable 1:14 risk-reward geometry against a Street consensus target of ~$645 with 52-week resistance at $663.57. Execute entry via staged adds in the $635-$650 pullback zone at 50-75% of normal sizing with stop at $593; Q3 2026 earnings (late October) is the binary catalyst that will either confirm or break the breakout, while trim triggers sit at $675-$690 on confirmed volume/RSI exhaustion.

Outcome

✓

Return

+1.12%

Status

scored

Hold rating maintained at TMO ($651.45) with position sizing capped at 50% of benchmark per the 9/17 binding lesson on extension signal stacking; no fresh capital deployment above $640, with phased laddered entries only on pullback to $590-$635 zones (Stage 1 at $632-$635, Stage 2 at $622-$625, Stage 3 at $590-$595). Structural participation preserved while awaiting Q3 2026 earnings resolution to confirm breakout above $660 on volume ≥3M before reassessing to Overweight.

Outcome

✓

Return

-1.04%

Status

scored

Maintain TMO at modest underweight (50-70% benchmark weight) as the unanimous Hold verdict across all analysts deems current price too extended relative to fundamentals. The 43% rally in 130 days has created asymmetric risk—Street consensus at $645 versus $658 spot, with reward-to-risk of only 0.51-0.76:1 to $720-$750, failing to justify aggressive capital deployment at current levels. Execute patience: trim 20-25% at $675-$690 on expanding volume, add on pullbacks to $620-$635 (Stage 1) or $600-$610 (Stage 2), and let Q3 2026 earnings resolve the breakout.

Outcome

✓

Return

+1.53%

Status

scored

TMO at $648.43 is inside the $635-650 exhaustion zone but lacks confirmation (volume was 2.88M vs required 3M; RSI at 69.4 vs required >70). All analysts converge on HOLD at 50-70% of benchmark weight—preserving the structural thesis while waiting for either a $619-633 retest to add with conviction or a confirmed breakout above $650/2.5M volume. The framework has generated alpha on six consecutive prior Hold calls by refusing to chase unconfirmed breakouts.

Outcome

✓

Return

+1.10%

Status

scored

Maintain TMO at modest underweight (50-70% of benchmark) with HOLD rating as trim triggers activate near the $635-650 exhaustion zone at $641.39. Stage entry targets are $616-617 (1-1.5% starter) and $580-583 (2-3% on MACD confirmation), with hard structural stop at $536.40; reassess after Q3 2026 earnings in late October.

Outcome

✗

Return

+4.53%

Status

scored

Maintain TMO at Hold with 50-70% benchmark weight (modest underweight); no trimming warranted at current $613.62 as price remains well below the $635-650 exhaustion zone where trim discipline applies. Hard stop sits at $580 daily close on expanding volume with hard invalidation at $535 weekly close; Q3 2026 earnings (late October) serves as the thesis-resolver for re-evaluation.

Outcome

✓

Return

+0.62%

Status

scored

Maintain TMO at modest underweight (50-70% of benchmark) with a Hold label. Do not add at $609.82 given unfavorable near-term risk/reward (~3.8% upside to $633 vs. 5-12% downside to $578-560 = ~1:2 against). Execute staged reloads on pullback to $565-580 with constructive basing, or scale in on confirmed breakout above $640 with volume ≥2.5M.

Outcome

✓

Return

+1.10%

Status

scored

Maintain TMO at 50-70% benchmark weight with a HOLD rating—the position is already calibrated to the current cautious outlook and further trimming at $610-615 would replicate the alpha-destructive pattern from 9/1-9/2. The technical stack shows genuine deterioration (price below 10 EMA, Bollinger midline, and VWMA with MACD bearish cross at -4.88 histogram) but lacks regime-confirmation, so the framework is to wait for either the $635-650 exhaustion zone (trim 20-30%) or structural breakdown below $576.56 (trim 1/3) before acting.

Outcome

✓

Return

-0.41%

Status

scored

Maintain TMO at Hold with 80-90% benchmark weight as the rating-action split best monetizes the cautionary thesis without capitulating to fear at near-fair value ($605, near price target of $580). Stage new positions only at $585-595 on confirmed two-consecutive-closes with declining volume, using a cost-efficient collar (sell Dec $640 call, buy Dec $570 put) rather than naked puts; hard structural stop remains at $536 (200 SMA). Q3 2026 earnings (late October) is the primary thesis-resolver given the 7-week catalyst gap and hostile macro environment.

Outcome

✓

Return

+0.44%

Status

scored

Maintain TMO at modest underweight (80-90% of benchmark) with a two-tiered staged entry plan rather than adding at current $603 levels, where the Aggressive Analyst's claimed 3:1 risk/reward fails basic math (actual ~1.2:1). Initiate 1-1.5% starter position on weakness into $585-595 zone, then 2-3% on confirmed $572 retest with 50 SMA hold and MACD histogram contraction; trim 1/3 above $635 on expanding volume. Q3 2026 earnings (late October) is the fundamental thesis-resolver.

Outcome

✗

Return

-1.75%

Status

scored

The report maintains TMO at HOLD given the stretched entry point despite a strong structural bull case. Current price ($613-620) is deemed too high to add with unfavorable risk/reward (~0.67), while a primary add zone is identified at $570-581 contingent on momentum reset (RSI <40, MACD histogram turning positive). The structural stop sits at $560, with Q3 2026 earnings (late October) serving as the next fundamental thesis-resolver.

Outcome

–

Return

-0.75%

Status

scored

Thermo Fisher Scientific Inc. receives an UNDERWEIGHT rating with a HOLD action, maintaining the current 50-70% target weight with no additional trimming. The execution architecture calls for staged adds (30-40% initial) if price reaches $600 with positive MACD confirmation or the $580-$600 zone, with a structural stop at $568 (between 50 SMA and 200 SMA). The position is calibrated below benchmark given 33x trailing P/E, elevated net leverage (3.3x), and fresh bearish MACD despite the +19.5% rally; re-evaluation is scheduled post-Q3 2026 earnings in late October.

Outcome

✗

Return

+1.63%

Status

scored

Trim 25% of the TMO position immediately at $608, retaining 75% as a core residual position. The $545 structural stop (between 50 SMA at $563 and 200 SMA at $535) protects against downside while the Underweight thesis plays out, with hard exit on weekly close below $535 and re-engagement only on confirmed FCF stabilization in the $520-$545 zone.

Outcome

✗

Return

+1.34%

Status

scored

The Portfolio Manager maintains an UNDERWEIGHT rating on TMO with an immediate SELL action to trim 30-40% of the overweight position at $629 spot, rejecting the trader's $645 stop as structurally broken and opting instead for a $580 structural floor stop on the residual half-weight position. The decision is anchored by the 8/31 lesson that waiting for trim zones to trigger results in alpha donation, with put spreads at $580/$540 strikes hedging Q3 earnings tail risk while preserving exposure to the franchise quality floor.

Outcome

✓

Return

-2.69%

Status

scored

Reduce TMO by 30-40% on rallies to $635-647, maintaining only a benchmark-capped core position. The 22.4x forward P/E offers no margin of safety versus the $629 DCF anchor, and the 2.06 PEG ratio signals speculative valuation in a no-cut Fed environment where re-rating is capped—leaving the entire thesis dependent on hitting $27.51 forward EPS at Q3 2026 earnings. Re-establish full weight only on a pullback to the $560-580 zone, while hedging residual exposure against sector rotation via a short in XBI or AVTR.

Outcome

✓

Return

-0.82%

Status

scored

Maintain TMO at benchmark weight with a Hold rating, avoiding additions at the current $619–625 zone where technicals (bearish MACD cross at swing high, lowest rally volume, 2.05 PEG) create poor risk-reward; pre-commit to a 2–3 tranche ladder targeting the $580–600 zone where reward-to-risk improves to ~2:1, trim 10–20% if price reaches $640–647 on expanding volume, and exit if weekly close breaks below $534.61 (200 SMA).

Outcome

✗

Return

-1.35%

Status

scored

Upgrade from Hold to Overweight justified by fair value convergence ($631.42 vs. $630 spot), cleared catalyst buffers (Agilent 8/26, Jackson Hole 8/21-23), and the prior Hold's relative-performance review threshold breach (-1.1% alpha on 8/26). Staged accumulation recommends 0.75-1% initial tranche at current levels with balance reserved for $605-618 pullback zone and $570-585 deeper adds; hard stop at $555 protects against thesis break while tolerating normal ATR volatility in this 0.85 beta name.

Outcome

✓

Return

-0.47%

Status

scored

Maintain TMO at benchmark weight with no addition at $633.71, which offers effectively zero margin of safety against the revised $631.42 fair value. Existing positions should be trailed at $612 (10 EMA close basis) while new tranches via the $610/$605/$600 buy ladder require stops set at $598 (~1.2x ATR below entry). Trimming is justified only on confirmed weakness (closing break of $616.30 with elevated volume AND fundamental deterioration), and all new capital deployment should be deferred through the Agilent (8/26) and Jackson Hole (8/21-23) catalyst windows.

Outcome

✓

Return

+0.89%

Status

scored

Maintain TMO at benchmark weight with $612 trailing stop, refraining from adding at $628 due to zero margin of safety against $631.42 fair value and stretched technicals (RSI 73.80, upper Bollinger tagged). Pre-commit to a $610/$605/$600 buy ladder triggered by 10 EMA/VWMA pullback with volume confirmation, post-Agilent (8/26) and Jackson Hole (8/21–23) catalysts, with new-entry stops at $604.

Outcome

✓

Return

-0.09%

Status

scored

Maintain TMO at benchmark weight as Hold is the correct posture given the conflict between strong structural fundamentals (golden cross intact, $6.24B TTM FCF, Q2'26 +10.5% revenue growth) and poor entry timing (RSI 74, price above upper Bollinger Band on declining volume). The existing tactical framework—trailing stop at $593, tactical add zone at $608-613, and trim zone at $634-640 with RSI >75—is correctly calibrated and requires no adjustment.

Outcome

✓

Return

-0.08%

Status

scored

TMO is rated HOLD at $629.27 with the existing position maintained at full benchmark weight and a $604 trailing stop; no new capital should be deployed at current prices given RSI 74, price above the upper Bollinger band, and 2.0 PEG with 48% earnings growth already priced in. A pre-committed buy ladder at $605/$600/$596 (equal-weighted thirds) will trigger upon Bollinger-band reset plus 10 EMA touch on volume of 1.8M-2M shares, subject to a catalyst buffer through the August 26 Agilent earnings and Jackson Hole events, with new-entry stops at $589 and a trim/hedge protocol of 15-25% profit-taking if price pushes into $640+ resistance without volume confirmation or RSI exceeds 75 with MACD histogram deepening negative.

Outcome

✓

Return

+0.27%

Status

scored

Maintain existing TMO at Hold given unfavorable near-term risk/reward (3.6% upside to $650 vs. 4.5% downside to $599), overbought conditions (RSI 74.24, price above Bollinger upper band at $620.87), and sub-confirmation volume (2.75M vs. 3M threshold); do not add at $627.55 but monitor for a staged breakout above $642.71–$650 on above-3M volume, with $586 as a structural reduction trigger and $538.70 as a major de-risking event.

Outcome

✓

Return

+2.28%

Status

scored

TMO remains on HOLD at $613.54—the structural quality floor (golden cross, 0.85 beta, $6.24B TTM FCF, 22.3x forward P/E) argues against Underweight, but overbought conditions (RSI 70.73, bearish MACD divergence, light-volume breakout on 1.68M shares vs 2-3M baseline) and elevated balance sheet risk ($42.55B debt, 3.3x net debt/EBITDA, -$20.8B tangible book) argue against new entries. The $585-588 stop (wider than the prior $592) accommodates TMO's 32% drawdown profile while preserving the position; staged triggers at $620 (starter), $642.71 (breakout confirmation), or $565-580 (pullback entry) provide disciplined re-engagement paths. The 12-month thesis awaits Q3 2026 earnings (~late October) as the first clean Olink integration readout.

Outcome

✗

Return

+4.16%

Status

scored

Reduce TMO to ~75% of benchmark weight with a 20% trim on any rally into the $605-$615 zone; avoid initiating new longs at ~$588-590. Hard stop at $560 (close on volume) triggers reduction to 50% benchmark weight. The $533 close invalidation warrants full exit. Park trimmed capital in short-duration Treasuries or money market until yields ease or TMO proves recovery at the $533-543 support cluster. Underweight reflects 27% PEG premium above fair value, flat 4-year revenue ($44.9B→$44.6B), 14.6% OCF decline with rising working capital, and 59% goodwill-to-assets structural risk—yet maintains ~75% weight due to $6.24B FCF floor and defensive 0.85 beta.

Outcome

✓

Return

+0.60%

Status

scored

Maintain TMO at current exposure as the $585 price sits between trim zone ($618-$644) and add zone ($605+), warranting passive hold; the hard stop at $533 remains the cleanest thesis-breaker, with Q3 2026 earnings (~10 weeks) serving as the timeline-resolver.

Outcome

✓

Return

-0.47%

Status

scored

Maintain TMO at neutral benchmark weight with Hold rating as the $588 entry lacks momentum support (fresh MACD bearish crossover, RSI rolling from 74, declining volume at 1.05M). Core thesis remains intact via Q2 reacceleration (+10.5% revenue), $6.24B FCF, and catalyst pipeline, but valuation is stretched at 21.4x forward PE requiring 48% EPS expansion. Explicit trim protocol at $620+ on volume confirmation preserves the ADD zone at $528-$550 for higher-quality re-engagement.

Outcome

✓

Return

-1.28%

Status

scored

The analyst recommends reducing TMO exposure to Underweight, calling for trimming into rallies at $596 with targets to $610-625 as resistance. The $644 level serves as the invalidation point if the stock breaks and holds above it on volume >2M with death cross resolution, while $525 is the downside target if any of three bear paths (valuation reset, technical breakdown, or Q1 2026 $8.87B acquisition integration stumble) materialize over 3-6 months.

Outcome

✓

Return

-1.18%

Status

scored

Maintain TMO without adding at $603 given stretched technicals (RSI 73, +15% above 50 SMA, fading volume at 1.19M vs 2-3M normal), despite Q2 reacceleration (+10.5% revenue, raised FY guidance) and durable four-segment moat supporting the structural thesis. Consider 15-25% profit-taking trim into $618-$644 resistance without confirmed breakout on volume >2M; re-engage on pullback to $586-$568 or confirmed break above $618 on heavy volume.

Outcome

✓

Return

-0.33%

Status

scored

Maintain TMO at $605 with a Hold rating as RSI 74.55, price at the upper Bollinger Band ($614.20), and declining volume (1.35M vs 2.1M average) create unfavorable entry asymmetry (~1.5% upside vs 3.6-12% downside). Use a tiered protocol: 25-33% starter on shallow dip holding $594-599, larger adds at $583-$565, or confirmation add above $614.20 on volume >2.1M. Working stop at 10 EMA ($583); hard invalidation below 200 SMA ($522). Reassess after Q3 earnings in late October.

Outcome

✓

Return

+0.89%

Status

scored

TMO is maintained at $599.69 without adding, as Q2 reacceleration (+10.5% revenue, +14.1% operating income) and FY guidance raise are offset by overbought conditions (RSI 73.2), resistance at $608.52 (upper Bollinger Band), and hostile macro (86% probability of zero 2026 Fed cuts). A tiered protocol is prescribed: trim 10-15% on a confirmed close above $608.52 on volume, add at $575-580 with a hard stop at $566, and trail stops at $583 (1× ATR). Reassess after golden cross confirmation and Q3 print in late October.

Outcome

✓

Return

+0.96%

Status

scored

Rated Overweight to capture confirmed Q2 reacceleration (+10.5% revenue, +14.1% operating income) and durable structural moat, but execute via phased entry rather than chase at $594. Position sizing of 2-3% portfolio weight reflects balance sheet concerns (net debt up 41% to $38.5B, 3.3x leverage, $54.8B goodwill), with a three-tranche deployment structure targeting $573-580 / $564 / $540-545 and stops at $560; full position requires successful integration of $8.87B Q1 acquisition and favorable Aug 12 CPI print.